InMed Pharmaceuticals Inc. (INM)
NASDAQ (CM) NASDAQ (CM) Primary Summary
InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday
On Tuesday, InMed Pharmaceuticals Inc. INM confirmed INM-901 as an oral formulation that will be utilized in its development programs for Alzheimer's disease.
InMed Pharmaceuticals Inc. (INM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has InMed Pharmaceuticals Inc. ever had a stock split?
InMed Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Eric A. Adams Chem., M.I.B. CEO | NASDAQ (CM) Exchange | 457637601 CUSIP |
| CA Country | 13 Employees | - Last Dividend | 14 Nov 2024 Last Split | 12 Nov 2020 IPO Date |
Overview
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the research, development, and commercialization of prescription-based products. Operating since 1981 and based in Vancouver, Canada, InMed Pharmaceuticals has evolved notably since its inception. Initially established as Cannabis Technologies Inc., the company underwent a name change in October 2014 to better reflect its expanded focus and commitment in the pharmaceutical sector. Its operations are divided into two main segments: the InMed segment, which is dedicated to researching and developing cannabinoid-based pharmaceutical products, and the BayMedica segment, which focuses on developing proprietary manufacturing technologies for producing and selling rare cannabinoids for the health and wellness industry.
Products and Services
- INM-755
- INM-088
- INM-900
- IntegraSyn
- Production of Rare Cannabinoids
A cannabinol topical skin cream designed for the treatment of epidermolysis bullosa, a rare and severe skin disorder. INM-755 has completed Phase 2 clinical trials, showcasing InMed Pharmaceuticals' dedication to addressing diseases with high unmet medical needs through innovative cannabinoid-based solutions.
InMed Pharmaceuticals is also working on INM-088 for the treatment of glaucoma, which is currently in preclinical studies. This effort underscores the company's commitment to expanding its cannabinoid-based product portfolio into areas of significant therapeutic potential.
Focused on addressing neurodegenerative diseases, INM-900 represents InMed Pharmaceuticals’ venture into treatments targeting conditions like Alzheimer's and Parkinson's diseases. Though still in the early stages, INM-900 exemplifies the company's long-term vision for contributing to the field of medicine through the exploration of cannabinoid application in neurodegenerative disorders.
IntegraSyn is InMed Pharmaceuticals' integrated biosynthesis-based manufacturing approach designed for producing pharmaceutical-grade cannabinoids. This innovative method supports the company’s commitment to supplying high-quality, rare cannabinoids for both therapeutic and wellness applications.
Under its BayMedica segment, InMed Pharmaceuticals develops proprietary manufacturing technologies to produce and commercialize rare cannabinoids such as cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. These efforts aim to serve the growing demand within the health and wellness industry for unique cannabinoid-based products.
Contact Information
